FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2061865937> ?p ?o ?g. }

• W2061865937 endingPage "176" @default.
• W2061865937 startingPage "167" @default.
• W2061865937 abstract "To evaluate the efficacy and safety of alogliptin, a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor, in combination with glyburide in patients with type 2 diabetes inadequately controlled by sulphonylurea monotherapy.After a 2-week screening period, adult patients 18-80 years of age entered a 4-week run-in/stabilization period in which they were switched from their own sulphonylurea medication to an equivalent dose of glyburide (open label) plus placebo (single blind). After the run-in period, patients were randomly assigned to double-blind treatment with alogliptin 12.5 mg (n = 203), alogliptin 25 mg (n = 198), or placebo (n = 99) for 26 weeks. The primary end-point was change from baseline to week 26 in glycosylated haemoglobin (HbA1c). Secondary end-points included clinical response rates and changes in fasting plasma glucose, beta-cell function (fasting proinsulin, insulin, proinsulin/insulin ratio, and C-peptide, and homeostasis model assessment beta-cell function), body weight, and safety end-points [adverse events (AEs), clinical laboratory tests, vital signs and electrocardiographic readings].The study population had a mean age of 57 years and a mean disease duration of 8 years; it was well balanced for gender (52% women) and was mainly white (71%). The mean baseline HbA1c was approximately 8.1% in each group. Significantly greater least squares (LS) mean reductions in HbA1c were seen at week 26 with alogliptin 12.5 mg (-0.38%) and 25 mg (-0.52%) vs. placebo (+0.01%; p < 0.001), and more patients in the alogliptin 25-mg group had HbA1c levels < or =7.0% at week 26 (34.8%, p = 0.002) vs. placebo (18.2%). Proportionately more patients in the alogliptin 12.5 mg (47.3%) and 25 mg (50.5%) groups had an HbA1c reduction > or =0.5% from baseline compared with patients in the placebo group (26.3%; p < 0.001). Minor improvements in individual markers of beta-cell function were seen with alogliptin, but no significant treatment group differences were noted relative to placebo. Minor LS mean changes in body weight were noted across groups (placebo, -0.20 kg; alogliptin 12.5 mg, +0.60 kg; alogliptin 25 mg, +0.68 kg). AEs were reported for 63-64% of patients receiving alogliptin and 54% of patients receiving placebo. Few AEs were treatment limiting (2.0-2.5% across groups), and serious AEs (2.0-5.6%) were infrequent, similar across groups, and generally considered not related to treatment. The incidences of hypoglycaemia for placebo, alogliptin 12.5 mg and alogliptin 25 mg groups were 11.1, 15.8 and 9.6% respectively.In patients with type 2 diabetes inadequately controlled by glyburide monotherapy, the addition of alogliptin resulted in clinically significant reductions in HbA1c without increased incidence of hypoglycaemia." @default.
• W2061865937 created "2016-06-24" @default.
• W2061865937 creator A5004465955 @default.
• W2061865937 creator A5011829580 @default.
• W2061865937 creator A5054183066 @default.
• W2061865937 creator A5059098934 @default.
• W2061865937 creator A5080806600 @default.
• W2061865937 date "2008-12-29" @default.
• W2061865937 modified "2023-10-10" @default.
• W2061865937 title "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy" @default.
• W2061865937 cites W1969389642 @default.
• W2061865937 cites W1986044732 @default.
• W2061865937 cites W1994832750 @default.
• W2061865937 cites W2005038357 @default.
• W2061865937 cites W2042129134 @default.
• W2061865937 cites W2064780710 @default.
• W2061865937 cites W2084403835 @default.
• W2061865937 cites W2089095955 @default.
• W2061865937 cites W2103516789 @default.
• W2061865937 cites W2126774100 @default.
• W2061865937 cites W2132802847 @default.
• W2061865937 cites W2153449155 @default.
• W2061865937 cites W2159205789 @default.
• W2061865937 cites W2162037642 @default.
• W2061865937 cites W2164961795 @default.
• W2061865937 cites W4210559565 @default.
• W2061865937 doi "https://doi.org/10.1111/j.1463-1326.2008.01016.x" @default.
• W2061865937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19125778" @default.
• W2061865937 hasPublicationYear "2008" @default.
• W2061865937 type Work @default.
• W2061865937 sameAs 2061865937 @default.
• W2061865937 citedByCount "149" @default.
• W2061865937 countsByYear W20618659372012 @default.
• W2061865937 countsByYear W20618659372013 @default.
• W2061865937 countsByYear W20618659372014 @default.
• W2061865937 countsByYear W20618659372015 @default.
• W2061865937 countsByYear W20618659372016 @default.
• W2061865937 countsByYear W20618659372017 @default.
• W2061865937 countsByYear W20618659372018 @default.
• W2061865937 countsByYear W20618659372019 @default.
• W2061865937 countsByYear W20618659372020 @default.
• W2061865937 countsByYear W20618659372021 @default.
• W2061865937 countsByYear W20618659372022 @default.
• W2061865937 countsByYear W20618659372023 @default.
• W2061865937 crossrefType "journal-article" @default.
• W2061865937 hasAuthorship W2061865937A5004465955 @default.
• W2061865937 hasAuthorship W2061865937A5011829580 @default.
• W2061865937 hasAuthorship W2061865937A5054183066 @default.
• W2061865937 hasAuthorship W2061865937A5059098934 @default.
• W2061865937 hasAuthorship W2061865937A5080806600 @default.
• W2061865937 hasConcept C126322002 @default.
• W2061865937 hasConcept C134018914 @default.
• W2061865937 hasConcept C142724271 @default.
• W2061865937 hasConcept C197934379 @default.
• W2061865937 hasConcept C204787440 @default.
• W2061865937 hasConcept C27081682 @default.
• W2061865937 hasConcept C2776453732 @default.
• W2061865937 hasConcept C2777180221 @default.
• W2061865937 hasConcept C2778763485 @default.
• W2061865937 hasConcept C2779284873 @default.
• W2061865937 hasConcept C2779306644 @default.
• W2061865937 hasConcept C2780012697 @default.
• W2061865937 hasConcept C2908647359 @default.
• W2061865937 hasConcept C555293320 @default.
• W2061865937 hasConcept C71924100 @default.
• W2061865937 hasConcept C90061646 @default.
• W2061865937 hasConcept C90924648 @default.
• W2061865937 hasConcept C98274493 @default.
• W2061865937 hasConcept C99454951 @default.
• W2061865937 hasConceptScore W2061865937C126322002 @default.
• W2061865937 hasConceptScore W2061865937C134018914 @default.
• W2061865937 hasConceptScore W2061865937C142724271 @default.
• W2061865937 hasConceptScore W2061865937C197934379 @default.
• W2061865937 hasConceptScore W2061865937C204787440 @default.
• W2061865937 hasConceptScore W2061865937C27081682 @default.
• W2061865937 hasConceptScore W2061865937C2776453732 @default.
• W2061865937 hasConceptScore W2061865937C2777180221 @default.
• W2061865937 hasConceptScore W2061865937C2778763485 @default.
• W2061865937 hasConceptScore W2061865937C2779284873 @default.
• W2061865937 hasConceptScore W2061865937C2779306644 @default.
• W2061865937 hasConceptScore W2061865937C2780012697 @default.
• W2061865937 hasConceptScore W2061865937C2908647359 @default.
• W2061865937 hasConceptScore W2061865937C555293320 @default.
• W2061865937 hasConceptScore W2061865937C71924100 @default.
• W2061865937 hasConceptScore W2061865937C90061646 @default.
• W2061865937 hasConceptScore W2061865937C90924648 @default.
• W2061865937 hasConceptScore W2061865937C98274493 @default.
• W2061865937 hasConceptScore W2061865937C99454951 @default.
• W2061865937 hasIssue "2" @default.
• W2061865937 hasLocation W20618659371 @default.
• W2061865937 hasLocation W20618659372 @default.
• W2061865937 hasOpenAccess W2061865937 @default.
• W2061865937 hasPrimaryLocation W20618659371 @default.
• W2061865937 hasRelatedWork W1554365987 @default.
• W2061865937 hasRelatedWork W2017061308 @default.
• W2061865937 hasRelatedWork W2094997999 @default.
• W2061865937 hasRelatedWork W2263964749 @default.
• W2061865937 hasRelatedWork W2385294593 @default.

• next